This variability highlights the importance of personalized risk stratification, particularly in patients with pre-existing strictures or baseline motility disorders, who may be at higher risk for chronic complications
By promoting insulin secretion and reducing glucagon levels, it helps regulate glucose, especially after meals, lowering the risk of hyperglycemia (high blood sugar)
The SURPASS-4 clinical trial was a non-inferiority study comparing tirzepatide to insulin glargine where tirzepartide showed superior A1c and body weight reductions from baseline in adults with T2DM at increased CVD risk.[20] Also, tirzepatide reported a higher occurrence of individuals achieving an A1c below 7% compared to insulin glargine
However, not all individuals experience these side effects
Its core mechanisms are closely related to disorders of cellular energy metabolism, accumulation of oxidative stress, and reduced capacity for DNA damage repair